 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update. 